Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fermented Wheat Germ in Advanced Malignancies Treated With Checkpoint Inhibitors
NCT05967533Phase 1Suspended
- Sponsor
- University of California, Davis
- Start
- Jun 2023
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fermented wheat germ extract in non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), melanoma and 2 more, sponsored by University of California, Davis. Primary endpoint: Natural killer cell killing activity at Day 4. Started Jun 2023; status: suspended.
02
Drugs
fermented wheat germ extract
03
Conditions
non-small cell lung carcinoma (NSCLC)renal cell carcinoma (RCC)melanomacolorectal carcinoma (CRC)breast carcinoma
Beyond the preview
Go deeper on NCT05967533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05967533.